Pfizer top R&D spender worldwide

Hey, big spenders: Pfizer shelled out more on R&D last year than any other company in the world, and drug makers in general have stepped up their research budgets, the European Commission says. Not surprising, considering the leaks in Big Pharma pipelines--and looming threat of blockbusters going off-patent.

Pfizer spent $8.18 billion, elbowing Ford out of the top slot. Johnson & Johnson came in third. Merck boosted its spending by 24 percent, AstraZeneca by 15 percent; J&J by 13 percent; and GlaxoSmithKline by 10 percent. The question is whether the outlay will do much good.

- see the EU's press release
- read the AP report article

ALSO: Pfizer announced that it has hired a new R&D chief and launched a biotech center. Report

Related Articles:
Where's the ROI on drug R&D budgets? Report
Pfizer's future rests with biotech. Report
Pfizer to invest $50M in biotech start-ups. Report
Pfizer goes public with R&D pipeline. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.